Tue, Oct 21, 2014, 8:05 AM EDT - U.S. Markets open in 1 hr 25 mins

Recent

% | $
Quotes you view appear here for quick access.

ADVANCED CELL TECH Message Board

  • btimnextmicrosoft btimnextmicrosoft Jan 7, 2014 8:24 PM Flag

    Gut feeling about Lanza

    After reading this...

    ....can't help but thing Dr. Anglade's CMO position might be a replacement for Lanza as CSO. Lanza is very creative and needs to take it to the next level. IMO i see him joining BTX to head ReCyte which is a BTX subsidiary licensing ACTC's IP. Merger or jump ship, either way i think it very probable being that Lanza and Dr. West have a loing history together and that BTX has gobbled up GERN's hESC IP.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • thx for the replies. My gut may be wrong, but i only posted this for a couple of reasons.
      A) ACTC practically gave away their ACTcellerate ip to BTX.
      B)Lanza can walk and take his patents elsewhere
      C)...and who licenses ACTC's IPS cell IP?... Biotimes subsidiary ReCyte.

      The other thing is that ACTC was first out of the gate with their AMD trials and as a result others are learning from their mistakes. BTW Biotime and TEVA will announce their AMD trials shortly. The only difference between the two is that Biotimes product will be 'zeno(animal)free'.

    • Hard to imagine he would jump ship but then we are talking ACTC and a CEO that is a total embarrassment . ACTC was supposed to be the industry leader for Stem Cells after Geron took their exit. I guess we all new this could happen but we were drinking the Cool Aid.

    • I do not think that Lanza will join BioTime. It's not only Dr. West, he can't stand but also Dr. Okarma who now is at Asteria, a BioTime subsidiary. If Drs. West and Okarma have joined hands, Lanza, if he joins BioTime, will remain an outcast!! Besides, why would Lanza leave ACTC, leaving all his life's accomplishments to someone else?!!!

    • It doesn't make sense. Everyone is clammering for news about his contract and Gary isn't delivering.

    • Don't know about this but I do get the gut feeling that something is not right here. When the publication about is being prepared people will know and we should see a rise on small buys. Not seeing that is disturbing.

    • Re: "....can't help but thing Dr. Anglade's CMO position might be a replacement for Lanza as CSO. Lanza is very creative and needs to take it to the next level. IMO i see him joining BTX to head ReCyte which is a BTX subsidiary licensing ACTC's IP. Merger or jump ship, either way i think it very probable being that Lanza and Dr. West have a loing history together and that BTX has gobbled up GERN's hESC IP."

      And, btim, why do you think West left ACT? Could it possibly be because he and Lanza had differences about the direction in which ACT should move and Lanza won the argument? I suggest that notions of Lanza and West getting back together in a serious and real way should not be taken seriously.

      Sentiment: Strong Buy

      • 2 Replies to elk_1l
      • "And, btim, why do you think West left ACT? Could it possibly be because he and Lanza had differences about the direction in which ACT should move and Lanza won the argument? "

        Elk, it wasn't West and Lanza that didn't get along, ir was Caldwell and West that were at odds on how to finance operations. And if you believe that Caldwell was right and West wrong, just compare how well BTX is doing compared to ACTC today.

        " I suggest that notions of Lanza and West getting back together in a serious and real way should not be taken seriously"

        Has Dr Lanza renewed his contract with ACT yet? NO!!!!!!!!!

      • Re: .........why do you think West left ACT? Could it possibly be because he and Lanza had differences about the direction in which ACT should move and Lanza won the argument?..........

        "By 2007, West says, he was not getting along with Caldwell and left ACT to head another company to develop products for ES-cell research. "

        NATURE | NEWS FEATURE
        Stem-cell research: Never say die --- Corie Lok
        11 January 2012

        : )

 
ACTC
7.08-0.10(-1.39%)Oct 20 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.